0.00
—
Close of 26 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RVL Pharmaceuticals
Its shares trade under the ticker RVLPQ. It has been listed since 12 October 2018. In the fiscal year to 31 December 2022, it reported revenue of $49.7m and a net loss of $51.7m. At that date it held total assets of $128.5m and shareholders' equity of $51.1m.
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey. The company went IPO on 2018-10-12. The firm is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The firm sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Oct 2018
- Employees
- 379
- Website
- osmotica.com ↗
Leadership
Pay as last reported
- Mr. Brian MarkisonChairman of the Board, Chief Executive Officer, Chief Financial Officer, since 2016$525,000
- Mr. James SchaubChief Operating Officer, Executive Vice President$367,200
- Mr. Christopher KleinGeneral Counsel, Secretary$367,200
- Mr. Gregory CowanNon-Executive Independent Director$234,000
- Mr. Michael DebiasiNon-Executive Independent Director$309,100
- Ms. Alisa LaskNon-Executive Independent Director$159,939
- Ms. Lisa WilsonIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 25
- Social
- 35
- Governance
- 12
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Osmotica Pharmaceuticals PLC has several strengths that contribute to its success in the market. The company boasts a diverse portfolio of pharmaceutical products, catering to a wide range of therapeutic areas. This allows them to tap into multiple revenue streams and mitigate the risks associated with relying on a single product or market segment.
- Additionally, Osmotica Pharmaceuticals PLC has a strong research and development team, continuously striving to innovate and develop new drugs. This expertise in drug discovery and development gives them a competitive edge in the industry and allows them to bring novel and effective medications to the market.
Weaknesses
- Osmotica Pharmaceuticals PLC also faces certain weaknesses that need addressing. One of the main concerns is the limited market presence compared to some of its larger competitors. This limited reach might hinder their ability to penetrate new markets and compete effectively against well-established pharmaceutical companies.
- Additionally, the company heavily relies on external suppliers for key raw materials and ingredients. This reliance on third-party suppliers poses a risk of potential disruptions in the supply chain, which could impact their manufacturing capabilities and product availability.
Opportunities
- Osmotica Pharmaceuticals PLC has several opportunities to capitalize on in the market. One such opportunity is the growing demand for generic medications. As patents for various branded drugs expire, there is an increasing need for cost-effective alternatives. Osmotica Pharmaceuticals PLC can leverage its expertise in generic drug development to gain market share in this segment.
- Furthermore, the global trend towards personalized medicine presents an opportunity for Osmotica Pharmaceuticals PLC to develop targeted therapies tailored to specific patient populations. This approach could enhance treatment outcomes and potentially lead to higher market demand for their specialized medications.
Threats
- Osmotica Pharmaceuticals PLC faces various threats that could impact its business. One significant threat is the stringent regulations and compliance requirements governing the pharmaceutical industry. Changes in regulations, particularly related to drug approvals and marketing, can significantly impact their product development timelines and marketing strategies.
- Economic factors, such as fluctuations in currency exchange rates and government healthcare policies, pose potential threats to Osmotica Pharmaceuticals PLC's profitability and market expansion. Additionally, intense competition within the pharmaceutical industry and the introduction of new market entrants could erode their market share and pricing power.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.